Patients with sinusitis, bronchitis, and uncomplicated urinary tract infections (UTIs) should receive fluoroquinolone antibacterial drugs only if other treatment options aren’t available, the FDA has advised.
In a Drug Safety Communication, the agency warned that systemic fluoroquinolones are associated with disabling and potentially permanent adverse effects involving tendons, muscles, nerves, and the central nervous system (http://1.usa.gov/1rIo90i).
Voelker R. New Fluoroquinolone Warning. JAMA. 2016;315(23):2514. doi:10.1001/jama.2016.7290